Fresenius Kabi Deutschland GmbH has awarded Duke Anesthesiology’s Niccolò Terrando, BSc (hons), DIC, PhD, a one-year, $122,000 grant for his project, titled “Omegaven and Postoperative Cognitive Dysfunction.”
“We are excited to initiate this collaboration and address the potential therapeutic effects of omega-3 supplementation on resolution of inflammation and cognitive function with our preclinical platforms,” says Dr. Terrando.
Perioperative neurocognitive disorders (PND), including acute postoperative delirium and longer-lasting postoperative cognitive dysfunction, are frequent complications following common surgical procedures. Metabolic disorders, including obesity, diabetes, and hypertension, increase the risk for PND and contribute to significantly higher mortality. Currently, no effective therapies exist to mitigate and possibly prevent PND.
Dr. Terrando’s proposal will evaluate the effects of omega-3 fatty acid supplementation, using Omegaven® as part of a project with Fresenius Kabi Deutschland GmbH, on postoperative neuroinflammation and cognitive dysfunction after orthopedic surgery in a mouse model of hypertension and PND. This builds on the expertise from Dr. Terrando’s Neuroinflammation and Cognitive Outcomes Laboratory to develop strategies to modulate neuroinflammation using pro-resolving mediators derived from natural compounds, such as omega-3 fatty acids. Completion of this work may lead to the implementation of novel strategies to prevent PND by enhancing brain resilience and healing using complementary approaches.
Duke Anesthesiology’s Dr. Paul Wischmeyer, who has spent his career partnering with Fresenius on similar projects, connected the company and Dr. Terrando. He says, “I saw an excellent opportunity to pair the exceptional work and expertise Dr. Terrando has built in PND with the real-world potential of Fresenius’ longstanding intravenous omega-3 infusion product, Omegaven. I think this is one of those rare and unique opportunities to perform a translational project that could have immediate clinical application to improve patients’ cognitive recovery.”